Navigation Links
Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
Date:5/7/2008

t of payments and fees, if any, from Arena's collaborators, and Arena's ability to redeem with common stock any outstanding shares of its series B convertible preferred stock. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners

Media Relations

David Walsey 212.301.7228

Director, Corporate Communications

Arena Pharmaceuticals, Inc.

858.453.7200, ext. 1682

Arena Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

Three months ended March 31,

2008 2007

(unaudited)

Revenues

Contract manufacturing $2,019 $ -

Collaborative agreements 590 4,911

Total revenues 2,609 4,911

Operating Expenses

Cost of contract manufacturing 2,330 -

Research and development 47,565 35,755

General and administrative 8,861 4,923

Amortization of acquired technology 3
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 ... technologies such as the Bioruptor® and complete solutions ... system for chromatin immunoprecipitation, alleviating the need for ... and controls needed for ChIP of histones or ...
(Date:1/22/2015)... Jan. 22. 2015  Varian Medical Systems (NYSE: VAR ... honored for its commitment to sustainability with inclusion on a ... the highest ranked healthcare equipment company among the Corporate Knights ... World Economic Forum at Davos, Switzerland . ...
(Date:12/25/2014)... The report “Service Quality Management and Telco Customer ... - Global Advancements, Worldwide Forecasts & Analysis (2014-2019)” defines ... forecasting of revenues. , Browse 152 market data ... TOC on “Service Quality Management (SQM) and Telco Customer ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Varian Honored Among World's 100 Most Sustainable Corporations 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... , THE WOODLANDS, Texas, Sept. 9 ... company focused on discovering and developing breakthrough treatments for human disease, announced ... president and chief executive officer, will present at the Morgan Stanley Global ... York on Tuesday, September 15, 2009 at 1:35 p.m. Eastern Time. ...
... ... software makes its debut at leading industry conferences. , ... Cambridge, MA (PRWEB) September 9, 2009 -- Akaza Research, the leading ... flagship product, OpenClinica, at two major industry conferences this fall. , , ,Representatives from Akaza ...
... Ontario, Sept. 8 Helix BioPharma Corp. (TSX, FSE: "HBP"; OTCQX: "HXBPF") ... 6,625,000 units at $2.05 per unit. , , ... purchase warrant, with each common share purchase warrant entitling the holder to ... price of $2.87 for up to three years after the closing date ...
Cached Biology Technology:Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2Akaza Research to Present OpenClinica 3.0 at Upcoming Clinical Research Conferences: SoCRA, SCDM 2Helix BioPharma Closes Private Placement 2Helix BioPharma Closes Private Placement 3
(Date:12/11/2014)... Dec. 10, 2014  That blood pressure plays a role in ... – the medical term for high blood pressure – was ... the inflatable cuff that,s used in measuring blood pressure was ... nothing new about hypertension, its triggers and its effects. In ...
(Date:12/10/2014)... Dec. 9, 2014  Valencell, a leader in performance biometric ... staggering demand from its licensees for highly accurate, clinically ... not solely coming from fitness and health sectors, but ... "A wearable is only as useful as the biometric ...
(Date:12/10/2014)... Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ) has announced the ... report to their offering. ... and smart cards for projects such as rural banking ... the major trends witnessed in the market. Besides the ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... a breakthrough in rechargeable battery applications. Gurpreet Singh, ... student researchers are the first to demonstrate that a ... graphene nanosheets -- can be both an active material ... collector. The newly developed composite paper can be used ...
... Dame, Resources for the Future, and the U.S. Forest ... Asian carp prevention barriers could be in a study ... Technology . , "Our study goes beyond ... effective various barriers will be, including hydrologic separation and ...
... China can build its way to a more energy efficient ... time by improving the rules regulating these structures, according ... National Laboratory. PNNL scientists at the Joint Global Change ... College Park, Md., have created a unique model that projects ...
Cached Biology News:Engineer brings new twist to sodium-ion battery technology 2Study measures how well Asian carp prevention effort will work 2Modeling buildings by the millions: Building codes in China tested for energy savings 2Modeling buildings by the millions: Building codes in China tested for energy savings 3Modeling buildings by the millions: Building codes in China tested for energy savings 4